A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.

There is need for improved human influenza vaccines, particularly for older adults who are at greatest risk for severe disease, as well as to address the continuous antigenic drift within circulating human subtypes of influenza virus. We have engineered an influenza virus-like particle (VLP) as a ne...

Full description

Bibliographic Details
Main Authors: Ted M Ross, Kutub Mahmood, Corey J Crevar, Kirsten Schneider-Ohrum, Penny M Heaton, Rick A Bright
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-06-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2698286?pdf=render
_version_ 1818518233525780480
author Ted M Ross
Kutub Mahmood
Corey J Crevar
Kirsten Schneider-Ohrum
Penny M Heaton
Rick A Bright
author_facet Ted M Ross
Kutub Mahmood
Corey J Crevar
Kirsten Schneider-Ohrum
Penny M Heaton
Rick A Bright
author_sort Ted M Ross
collection DOAJ
description There is need for improved human influenza vaccines, particularly for older adults who are at greatest risk for severe disease, as well as to address the continuous antigenic drift within circulating human subtypes of influenza virus. We have engineered an influenza virus-like particle (VLP) as a new generation vaccine candidate purified from the supernatants of Sf9 insect cells following infection by recombinant baculoviruses to express three influenza virus proteins, hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1). In this study, a seasonal trivalent VLP vaccine (TVV) formulation, composed of influenza A H1N1 and H3N2 and influenza B VLPs, was evaluated in mice and ferrets for the ability to elicit antigen-specific immune responses. Animals vaccinated with the TVV formulation had hemagglutination-inhibition (HAI) antibody titers against all three homologous influenza virus strains, as well as HAI antibodies against a panel of heterologous influenza viruses. HAI titers elicited by the TVV were statistically similar to HAI titers elicited in animals vaccinated with the corresponding monovalent VLP. Mice vaccinated with the TVV had higher level of influenza specific CD8+ T cell responses than a commercial trivalent inactivated vaccine (TIV). Ferrets vaccinated with the highest dose of the VLP vaccine and then challenged with the homologous H3N2 virus had the lowest titers of replicating virus in nasal washes and showed no signs of disease. Overall, a trivalent VLP vaccine elicits a broad array of immunity and can protect against influenza virus challenge.
first_indexed 2024-12-11T01:07:12Z
format Article
id doaj.art-14af2c4438a44b5289d0c01d2e0f754c
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T01:07:12Z
publishDate 2009-06-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-14af2c4438a44b5289d0c01d2e0f754c2022-12-22T01:26:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032009-06-0146e603210.1371/journal.pone.0006032A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.Ted M RossKutub MahmoodCorey J CrevarKirsten Schneider-OhrumPenny M HeatonRick A BrightThere is need for improved human influenza vaccines, particularly for older adults who are at greatest risk for severe disease, as well as to address the continuous antigenic drift within circulating human subtypes of influenza virus. We have engineered an influenza virus-like particle (VLP) as a new generation vaccine candidate purified from the supernatants of Sf9 insect cells following infection by recombinant baculoviruses to express three influenza virus proteins, hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1). In this study, a seasonal trivalent VLP vaccine (TVV) formulation, composed of influenza A H1N1 and H3N2 and influenza B VLPs, was evaluated in mice and ferrets for the ability to elicit antigen-specific immune responses. Animals vaccinated with the TVV formulation had hemagglutination-inhibition (HAI) antibody titers against all three homologous influenza virus strains, as well as HAI antibodies against a panel of heterologous influenza viruses. HAI titers elicited by the TVV were statistically similar to HAI titers elicited in animals vaccinated with the corresponding monovalent VLP. Mice vaccinated with the TVV had higher level of influenza specific CD8+ T cell responses than a commercial trivalent inactivated vaccine (TIV). Ferrets vaccinated with the highest dose of the VLP vaccine and then challenged with the homologous H3N2 virus had the lowest titers of replicating virus in nasal washes and showed no signs of disease. Overall, a trivalent VLP vaccine elicits a broad array of immunity and can protect against influenza virus challenge.http://europepmc.org/articles/PMC2698286?pdf=render
spellingShingle Ted M Ross
Kutub Mahmood
Corey J Crevar
Kirsten Schneider-Ohrum
Penny M Heaton
Rick A Bright
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
PLoS ONE
title A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
title_full A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
title_fullStr A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
title_full_unstemmed A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
title_short A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
title_sort trivalent virus like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets
url http://europepmc.org/articles/PMC2698286?pdf=render
work_keys_str_mv AT tedmross atrivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT kutubmahmood atrivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT coreyjcrevar atrivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT kirstenschneiderohrum atrivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT pennymheaton atrivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT rickabright atrivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT tedmross trivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT kutubmahmood trivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT coreyjcrevar trivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT kirstenschneiderohrum trivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT pennymheaton trivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets
AT rickabright trivalentviruslikeparticlevaccineelicitsprotectiveimmuneresponsesagainstseasonalinfluenzastrainsinmiceandferrets